{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:41:03Z","timestamp":1791351663475,"version":"4.3.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000282","name":"Sir Jules Thorn Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jhepr.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T03:01:42Z","timestamp":1572922902000},"page":"437-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group"],"prefix":"10.1016","volume":"1","author":[{"given":"Nwe Ni","family":"Than","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schmidt-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Wawman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meemee","family":"Botter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham D","family":"Appanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Godkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo J.","family":"Montano-Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly W.","family":"Burak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Htun","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2019.10.005_bb0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","volume":"63","author":"Lohse","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12072-016-9727-4","article-title":"Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients","volume":"10","author":"Than","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.12940","article-title":"Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases","volume":"188","author":"Jeffery","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0020","first-page":"7181685","article-title":"Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy","volume":"2016","author":"Than","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0025","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/hep.29307","article-title":"Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis\/Autoimmune Sclerosing Cholangitis","volume":"66","author":"Liberal","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0030","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1053\/j.gastro.2008.07.029","article-title":"Identification of CD4 T-cell epitopes in soluble liver antigen\/liver pancreas autoantigen in autoimmune hepatitis","volume":"135","author":"Mix","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0035","first-page":"133","article-title":"Autoimmune hepatitis 2013 and beyond","volume":"59","author":"Weiler-Normann","year":"2013","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0040","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0050","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","article-title":"Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs","volume":"36","author":"Selvarajah","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0065","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","article-title":"Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease","volume":"46","author":"Montano-Loza","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0070","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2174\/157488412803305812","article-title":"The treatment of autoimmune hepatitis","volume":"7","author":"Malnick","year":"2012","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","article-title":"Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy","volume":"51","author":"Than","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3350\/cmh.2016.0089","article-title":"The use of immunosuppression in autoimmune hepatitis: A current literature review","volume":"23","author":"Cropley","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0095","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","article-title":"Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome","volume":"139","author":"Carey","year":"2011","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12470","article-title":"Review article: autoimmune hepatitis -- current management and challenges","volume":"38","author":"Zachou","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.13458","article-title":"Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda","volume":"38","author":"Sebode","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","article-title":"Consequences of treatment withdrawal in type 1 autoimmune hepatitis","volume":"27","author":"Montano-Loza","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.13907","article-title":"Expert clinical management of autoimmune hepatitis in the real world","volume":"45","author":"Liberal","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0120","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0130","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s10620-017-4675-y","article-title":"Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis","volume":"62","author":"Czaja","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0150","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0155","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0160","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0165","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0170","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/liv.14051","article-title":"Review article: stopping immunosuppressive treatment in autoimmune hepatitis (AIH): is it justified (and in whom and when)","volume":"39","author":"Harrison","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1556743","article-title":"Update on the Teratogenicity of Maternal Mycophenolate Mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J Pediatr Genet"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0185","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0190","first-page":"193","article-title":"Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis: Interim Analysis Report of a Randomized Controlled Trial","volume":"5","author":"Nasseri-Moghaddam","year":"2013","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0195","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1440-1746.2010.06579.x","article-title":"Treatment of autoimmune hepatitis: a review of current and evolving therapies","volume":"26","author":"Jothimani","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.15403\/jgld.2014.1121.251.hpe","article-title":"Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the Netherlands","volume":"25","author":"van Gerven","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35882-7","article-title":"Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis","volume":"8","author":"Taubert","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0210","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2014.08.002","article-title":"Long-term outcome in PSC\/AIH \"overlap syndrome\": does immunosuppression also treat the PSC component?","volume":"61","author":"Zenouzi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.mpg.0000239735.87111.ba","article-title":"Prospective analysis of nonadherence in autoimmune hepatitis: a common problem","volume":"43","author":"Kerkar","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0220","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","article-title":"Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis","volume":"60","author":"Schramm","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0225","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jhep.2012.07.032","article-title":"Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors","volume":"57","author":"Sockalingam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2013.06.016","article-title":"The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies","volume":"46","author":"Muratori","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0235","first-page":"364","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"l67","author":"Gottenberg","year":"2019","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0240","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ibanez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0255","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","article-title":"A Case of Autoimmune Hepatitis Treated with Rituximab","volume":"4","author":"Barth","year":"2010","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0260","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"D'Agostino","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajg.2013.08.009","article-title":"Rituximab for refractory autoimmune hepatitis: a case report","volume":"14","author":"Al-Busafi","year":"2013","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0270","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0275","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","article-title":"Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature","volume":"26","author":"Santos","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18773\/austprescr.2016.053","article-title":"Rituximab in autoimmune diseases","volume":"39","author":"Randall","year":"2016","journal-title":"Aust Prescr"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204772","article-title":"Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey","volume":"13","author":"Takahashi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2019.10.005_bb0295","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1163","article-title":"Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis","volume":"2","author":"Jeffery","year":"2018","journal-title":"Hepatol Commun"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919301272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919301272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:48Z","timestamp":1762899828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555919301272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2589555919301272"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.10.005","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}]}}